Refine by
Immuno Oncology Suppliers & Manufacturers
76 companies found
based inBrisbane, CALIFORNIA (USA)
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. ...
Enhanced genome editing with an expanded CRISPR toolkit: Our CRISPR-Cas systems provide unprecedented power to edit the ...
based inNew York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Prostate cancer is the most common type of cancer (aside from skin) in American men with 13 out of every 100 being diagnosed with the disease during their lifetime.1,2Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
based inSeattle, WASHINGTON (USA)
As the pioneer in the field of spatial biology, NanoString enables scientists across the globe to envision molecular interactions in three dimensions with three different systems, the nCounter Analysis System, the GeoMx Digital Spatial Profiler ...
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial ...
based in, MASSACHUSETTS (USA)
Thermo Scientific instruments, equipment, software, services and consumables empower scientists to solve for complex analytical challenges in pharmaceutical, biotechnology, academic, government, environmental and industrial research, as well as the ...
based inRehovot, ISRAEL
Biolojic Design is committed to curing patients by designing and developing a pipeline of revolutionary therapeutics. Biolojic’s platform generates antibodies that bind to predefined epitopes, thus allowing for the design of specific functions: ...
based inHamburg, GERMANY
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy. As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics ...
Cancer immunology, or “immuno-oncology,” is a growing field of research that aims to discover innovative cancer immunotherapies to treat and impede the progression of the disease. Understanding how ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
INOVOTION has developed a unique, highly sensitive and reproducible assay. It is applicable to all preclinical oncology and immuno-oncology drug discovery programs, and monitors the growth and ...
based inCounty of New Castle, DELAWARE (USA)
MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) ...
TCR profiling holds great potential not only for understanding the mechanisms of development of the normal immune response, but also in providing insights into disease mechanisms and development of new therapeutics and treatment modalities in ...
based inDurham, NORTH CAROLINA (USA)
Cancer is the second leading cause of death in the U.S. and metastatic disease remains predominantly incurable. New cancer cases and healthcare costs continue to increase year-over-year. Precision medicine aims to select the most effective ...
Xilis’ rapid and scalable patient-derived MicroOrganoSphere (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development. Compared to conventional patient-derived models, MOS provides faster, ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
based inMilan, ITALY
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies. Italfarmaco was establish in ...
MYELOSTIM® (lenograstim) is the only glycosylated granulocyte growth factor, indistinguishable from the native human one, effectively enabling to prevent and control bone marrow toxicity caused by the use of chemotherapeutic agents producing ...
based inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
DEP® irinotecan is an improved version of irinotecan (Camptosar®), predominantly used for colorectal cancer. DEP® irinotecan is a novel, patented nanoparticle formulation of SN-38, the active metabolite of irinotecan, delivered using ...
based inNew Haven, CONNECTICUT (USA)
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge ...
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to induction of IL-18 and ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
based inMenlo Park, CALIFORNIA (USA)
Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI (multiplexed ion beam imaging) platform breaks through the ...